» Articles » PMID: 36769405

Associations Between Systemic Immune-Inflammation Index and Diabetes Mellitus Secondary to Pancreatic Ductal Adenocarcinoma

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Feb 11
PMID 36769405
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is a high prevalence of diabetes mellitus (DM) in patients with pancreatic ductal adenocarcinoma (PDAC). An inflammatory response is considered as a potential mechanism involved in the process. The systemic immune-inflammation (SII) index is an integrated and novel inflammatory indicator developed in recent years. The purpose of this study was to determine the relationship between the SII and DM secondary to PDAC.

Method: Patients with a confirmed diagnosis of PDAC were analyzed in this cross-sectional study. Anthropometric measures, glucose-related data (including fasting glucose, 2 h OGTT, glycated hemoglobin, fasting insulin, and fasting c-peptide), tumor characteristics (tumor volumes, location and stages), and the periphery blood inflammatory index (white blood cell count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and SII) were recorded. The inflammation index was analyzed for its association with glucose-related parameters. Multivariable logistic regression analysis was used to analyze the association between SII levels and DM secondary to PDAC.

Results: Blood cell results showed that the white blood cell count, neutrophils, lymphocytes, monocytes, platelets, the neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio were higher in patients with diabetes. It was worth noting that SII significantly increased in patients with diabetes secondary to PDAC (4.41 vs. 3.19, < 0.0001). Multivariable logistic regression analysis showed that SII (OR: 2.024, 95%CI: 1.297, 3.157, = 0.002) and age (OR: 1.043, 95%CI: 1.01, 1.077, = 0.011) were the risk factors for DM secondary to PDAC after adjusting for covariates. According to Spearmen correlation analysis, SII was positively correlated with fasting glucose (r = 0.345, < 0.0001), 2 h OGTT (r = 0.383, < 0.0001), HbA1c (r = 0.211, = 0.005), fasting insulin (r = 0.435, < 0.0001), fasting C-peptide (r = 0.420, < 0.0001), and HOMA2-IR (r = 0.491, < 0.0001).

Conclusions: In conclusion, SII is significantly increased among patients with DM secondary to PDAC and is associated with the DM in patients with PDAC (OR: 2.382, 95% CI: 1.157, 4.903, = 0.019). Additionally, SII is significantly correlated with insulin resistance. We are the first to investigate the relationship between SII and diabetes secondary to PDAC and further confirm the role of an inflammatory response in this process. More studies need to be designed to clarify how inflammatory responses participate.

Citing Articles

Blood indices of inflammation and their association with hypertension in smokers: analysis using data mining approaches.

Ghoflchi S, Mansoori A, Islampanah M, Arab Yousefabadi S, Poudineh M, Derakhshan-Nezhad E J Hum Hypertens. 2024; 39(1):29-37.

PMID: 39472721 DOI: 10.1038/s41371-024-00975-6.


Systemic immune inflammation index and all-cause mortality in chronic kidney disease: A prospective cohort study.

Jia M, Yuan W, Chen Y, Wang Y, Shang L, Han S Immun Inflamm Dis. 2024; 12(9):e1358.

PMID: 39254488 PMC: 11386342. DOI: 10.1002/iid3.1358.


Association of the systemic immune-inflammation index (SII) and severity of diabetic ketoacidosis in patients with type 1 diabetes mellitus: a retrospective cohort study.

Aon M, Aoun A, Alshami A, Alharbi A, Alshammari F, Alnajjar M Ann Med Surg (Lond). 2024; 86(7):3865-3872.

PMID: 38989212 PMC: 11230746. DOI: 10.1097/MS9.0000000000002185.


Systemic immune-inflammation index and in-stent restenosis in patients with acute coronary syndrome: a single-center retrospective study.

Xie F, Yu Z, Xiong Y, Wu Z, Wu Y Eur J Med Res. 2024; 29(1):145.

PMID: 38409069 PMC: 10895800. DOI: 10.1186/s40001-024-01736-4.


Evaluating the Diagnostic Performance of Systemic Immune-Inflammation Index in Childhood Inflammatory Arthritis: A Focus on Differentiating Juvenile Idiopathic Arthritis from Reactive Arthritis.

Nicoara D, Munteanu A, Scutca A, Brad G, Asproniu R, Juganaru I Biomedicines. 2024; 12(1).

PMID: 38255172 PMC: 10812990. DOI: 10.3390/biomedicines12010065.


References
1.
Wang W, Liu X, Liu L, Jin D, Yang P, Wang X . Identification of proteins implicated in the development of pancreatic cancer-associated diabetes mellitus by iTRAQ-based quantitative proteomics. J Proteomics. 2013; 84:52-60. DOI: 10.1016/j.jprot.2013.03.031. View

2.
Hart P, Bellin M, Andersen D, Bradley D, Cruz-Monserrate Z, Forsmark C . Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2017; 1(3):226-237. PMC: 5495015. DOI: 10.1016/S2468-1253(16)30106-6. View

3.
Chari S, Zapiach M, Yadav D, Rizza R . Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology. 2005; 5(2-3):229-33. DOI: 10.1159/000085276. View

4.
Bittoni A, Pecci F, Mentrasti G, Crocetti S, Lupi A, Lanese A . Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. Ann Transl Med. 2021; 9(3):251. PMC: 7940927. DOI: 10.21037/atm-20-3499. View

5.
Wang X, Zheng X, Yan J, Xu R, Xu M, Zheng L . The Clinical Values of Afamin, Triglyceride and PLR in Predicting Risk of Gestational Diabetes During Early Pregnancy. Front Endocrinol (Lausanne). 2021; 12:723650. PMC: 8597949. DOI: 10.3389/fendo.2021.723650. View